Business & Finance In Brief
This article was originally published in The Tan Sheet
Merck CEO Frazier touts the value of OTCs for extending the drug life cycle; Abbott Nutrition plans nearly 40 product launches across 30 countries by 2017; Herbalife growth reflects global weight management and wellness concerns.
You may also be interested in...
Abbott Laboratories’ nutrition business – one of four divisions in the remaining diversified medical products firm – gains importance with the firm’s plan to spin off its research-based branded pharmaceuticals business.
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
Herbalife is hitching its growth and expansion plans to the daily consumption customer clubs organized by the direct-selling supplement firm's distributors, according to executive Rich Goudis